Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Vaccine vial

Similar stories

COVID-19 Impact Report

The CAMS-Oxford Institute (COI) has funded 12 COVID-19 projects aiming to understand immune responses to COVID-19, contributing nearly 100 published research articles to the field. Read about the impact the COI has had on our understanding of COVID-19 pathology and immunology.